ORC
ABBV icon

O'Rourke & Company’s AbbVie ABBV Stock Holding History

O'Rourke & Company’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$554K Sell
2,546
-32
-1% -$7.1K 0.22% 95
2025
Q4 		$589K Sell
2,578
-93
-3% -$21.2K 0.23% 92
2025
Q3 		$618K Sell
2,671
-32
-1% -$6.52K 0.26% 88
2025
Q2 		$502K Sell
2,703
-56
-2% -$10.4K 0.23% 91
2025
Q1 		$578K Sell
2,759
-81
-3% -$15.7K 0.29% 76
2024
Q4 		$505K Sell
2,840
-76
-3% -$14K 0.25% 82
2024
Q3 		$576K Buy
2,916
+3
+0.1% +$560 0.29% 74
2024
Q2 		$500K Buy
2,913
+3
+0.1% +$497 0.28% 72
2024
Q1 		$530K Buy
2,910
+3
+0.1% +$517 0.31% 68
2023
Q4 		$451K Buy
2,907
+7
+0.2% +$1.02K 0.29% 72
2023
Q3 		$432K Buy
2,900
+7
+0.2% +$1.03K 0.32% 64
2023
Q2 		$390K Sell
2,893
-27
-0.9% -$3.96K 0.27% 79
2023
Q1 		$465K Buy
2,920
+6
+0.2% +$917 0.35% 66
2022
Q4 		$471K Buy
2,914
+241
+9% +$37K 0.37% 63
2022
Q3 		$359K Sell
2,673
-20
-0.7% -$2.87K 0.31% 75
2022
Q2 		$412K Sell
2,693
-110
-4% -$16.8K 0.35% 69
2022
Q1 		$454K Buy
2,803
+145
+5% +$21.1K 0.31% 72
2021
Q4 		$360K Buy
+2,658
New +$314K 0.24% 82

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

O'Rourke & Company's ABBV Position: Q1 2026 in Review

O'Rourke & Company reduced its AbbVie (ABBV) stake by 1.2% in Q1 2026, selling an estimated $7.1K and leaving 2,546 shares worth $554K. The position accounts for 0.22% of the portfolio, ranked #95.

O'Rourke & Company first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $618K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • O'Rourke & Company held 2,546 shares of AbbVie worth $554K as of Q1 2026.
  • O'Rourke & Company sold 32 AbbVie shares in Q1 2026, an estimated $7.1K.
  • AbbVie made up 0.22% of O'Rourke & Company's portfolio in Q1 2026, its #95 holding.
  • O'Rourke & Company first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • O'Rourke & Company's AbbVie position peaked at $618K in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on O'Rourke & Company's 13F filing for Q1 2026, filed 14 May 2026.